BPC-13: Minority opinion on cyromazine in product type 18 (Insecticides, acaricides and products to control other arthropods)

The Swedish Competent Authority is seriously concerned by scientific data indicating the mutagenic properties of cyromazine. These indications have not been sufficiently addressed in the risk assessment of the substance. Therefore, the Swedish Competent Authority cannot agree with the proposal to approve cyromazine for the use in biocidal products.

Since change of genetic code (mutagenicity) is a serious adverse effect with impact for coming generations, the available indications presented in the assessment report should not have been taken as lightly as it has been done by the BPC-Working group for Human Health.

Since the majority of the BPC proposes to approve cyromazine in product type 18, Sweden submits a minority opinion.